ATE520682T1 - 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren - Google Patents

2-heteroarylaminopyrimidinderivate als kinaseinhibitoren

Info

Publication number
ATE520682T1
ATE520682T1 AT08798064T AT08798064T ATE520682T1 AT E520682 T1 ATE520682 T1 AT E520682T1 AT 08798064 T AT08798064 T AT 08798064T AT 08798064 T AT08798064 T AT 08798064T AT E520682 T1 ATE520682 T1 AT E520682T1
Authority
AT
Austria
Prior art keywords
raf
compounds
kinase inhibitors
abl
ameliorate
Prior art date
Application number
AT08798064T
Other languages
English (en)
Inventor
Donatella Chianelli
Valentina Molteni
Xiaolin Li
Xiaodong Liu
Juliet Nabakka
Jon Loren
Original Assignee
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc filed Critical Irm Llc
Application granted granted Critical
Publication of ATE520682T1 publication Critical patent/ATE520682T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
AT08798064T 2007-08-22 2008-08-18 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren ATE520682T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95724007P 2007-08-22 2007-08-22
PCT/US2008/073438 WO2009026204A1 (en) 2007-08-22 2008-08-18 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE520682T1 true ATE520682T1 (de) 2011-09-15

Family

ID=39930713

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08798064T ATE520682T1 (de) 2007-08-22 2008-08-18 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren

Country Status (13)

Country Link
US (1) US8288540B2 (de)
EP (1) EP2190836B1 (de)
JP (1) JP5303557B2 (de)
KR (1) KR101171488B1 (de)
CN (1) CN101784539A (de)
AT (1) ATE520682T1 (de)
AU (1) AU2008289135B2 (de)
BR (1) BRPI0815572A2 (de)
CA (1) CA2697077C (de)
EA (1) EA017392B1 (de)
ES (1) ES2368876T3 (de)
MX (1) MX2010002005A (de)
WO (1) WO2009026204A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
KR20120107538A (ko) 2007-08-22 2012-10-02 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물
PE20120061A1 (es) 2008-12-19 2012-02-19 Boehringer Ingelheim Int Derivados de pirimidina como antagonistas del receptor ccr2
PT3091012T (pt) 2009-12-17 2018-06-27 Centrexion Therapeutics Corp Antagonistas do receptor ccr2 e suas utilizações
JP2013526507A (ja) 2010-05-12 2013-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規ｃｃｒ２受容体アンタゴニスト、その製造方法及び薬物としてのその使用
US8946218B2 (en) 2010-05-12 2015-02-03 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8841313B2 (en) 2010-05-17 2014-09-23 Boehringer Ingelheim International Gmbh CCR2 antagonists and uses thereof
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ２受容体アンタゴニスト
EP2576538B1 (de) * 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH Neue CCR2-Antagonisten
AU2011283684B2 (en) 2010-07-29 2015-08-27 Rigel Pharmaceuticals, Inc. AMPK-activating heterocyclic compounds and methods for using the same
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なｃｃｒ２拮抗薬
BR112014001714A2 (pt) 2011-07-26 2017-02-14 Gruenenthal Gmbh derivados de carboxamida e ureia aromáticos bicíclicos substituídos como ligantes de receptor vaniloide
JO3405B1 (ar) 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
EP3007689B1 (de) 2013-01-10 2018-03-07 Pulmokine, Inc. Nicht-selektive kinasehemmer
EP3036262A4 (de) 2013-08-22 2017-03-01 Acceleron Pharma Inc. Varianten von tgf-beta-rezeptortyp ii und verwendungen davon
CN104458675A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种筛选干细胞因子受体激酶抑制剂高通量筛选方法
CN104458674A (zh) * 2013-09-12 2015-03-25 中国药科大学 一种筛选血管内皮生长因子1激酶抑制剂高通量筛选方法
CN106132403B (zh) 2013-10-11 2020-04-28 普尔莫凯恩股份有限公司 喷雾干燥制剂
EP3685848B1 (de) 2013-11-21 2021-09-15 The Brigham and Women's Hospital, Inc. Zusammensetzungen und verfahren zur behandlung pulmonaler hypertonie
CN106794233B (zh) 2014-08-01 2021-11-12 布里格姆及妇女医院股份有限公司 与肺动脉高压的治疗有关的组合物和方法
MX2017017177A (es) 2015-07-02 2018-11-09 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidi n-1-il)(5-metil-6-(((2r,6s)-6-(p-tolil)tetrahidro-2h-piran-2-il)m etilamino)pirimidin-4il) metanona.
KR20180035884A (ko) 2015-08-04 2018-04-06 악셀레론 파마 인코포레이티드 골수증식성 장애를 치료하기 위한 방법
WO2017066193A1 (en) 2015-10-15 2017-04-20 Princeton Drug Discovery, Llc Novel inhibitors of protein kinases
EP3481753B1 (de) 2016-07-06 2020-11-04 Tomra Systems ASA Vorrichtung und verfahren zur vereinzelung von gebrauchten getränke- oder lebensmittelbehältern
CA3041679A1 (en) 2016-10-27 2018-05-03 Lawrence S. ZISMAN Combination therapy for treating pulmonary hypertension
KR20240023201A (ko) 2017-05-04 2024-02-20 악셀레론 파마 인코포레이티드 Tgf-베타 수용체 유형 ii 융합 단백질 및 이의 용도
WO2018214866A1 (zh) * 2017-05-24 2018-11-29 上海和誉生物医药科技有限公司 一种氮杂芳基衍生物、其制备方法和在药学上的应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0164204A1 (de) 1984-05-12 1985-12-11 FISONS plc Pharmazeutisch nützliche Pyrimidine
CA2148931A1 (en) 1993-10-01 1995-04-13 Jurg Zimmermann Pyrimidineamine derivatives and processes for the preparation thereof
AU2048500A (en) * 1998-12-08 2000-06-26 Globespan Inc. A system and method for modifying symbol duration for the efficient transmissionof information in a time duplex noise enviroment
GB0022438D0 (en) 2000-09-13 2000-11-01 Novartis Ag Organic Compounds
US7429599B2 (en) 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7129242B2 (en) 2000-12-06 2006-10-31 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ATE331519T1 (de) 2001-05-16 2006-07-15 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
WO2003011836A1 (en) * 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
US7117491B2 (en) * 2002-08-29 2006-10-03 International Business Machines Corporation Method, system, and program for determining whether data has been modified
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
ES2229928B1 (es) * 2003-10-02 2006-07-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirimidin-2-amina.
MX2007002819A (es) 2004-09-09 2007-08-14 Natco Pharma Ltd Nuevos derivados de fenilaminopirimidina como inhibidores de bcl-abl cinasa.
KR20070084067A (ko) 2004-10-13 2007-08-24 와이어쓰 Ｎ-벤젠설포닐 치환 아닐리노-피리미딘 동족체
AU2005325676A1 (en) 2004-12-23 2006-08-03 Deciphera Pharmaceuticals, Llc Anti-inflammatory medicaments
EP1835934A4 (de) 2004-12-23 2010-07-28 Deciphera Pharmaceuticals Llc Enzymmodulatoren und behandlungen
US20060247250A1 (en) 2005-03-16 2006-11-02 Targegen, Inc. Pyrimidine inhibitors of kinases
KR100674813B1 (ko) 2005-08-05 2007-01-29 일양약품주식회사 Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법
AU2006297089B2 (en) * 2005-09-27 2012-05-03 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
WO2007053776A1 (en) * 2005-11-03 2007-05-10 Sgx Pharmaceuticals, Inc. Pyrimidinyl-thiophene kinase modulators
BRPI0718677A2 (pt) 2006-11-03 2013-11-26 Irm Llc Compostos e composições como inibidores de quinases proteicas
WO2008137794A1 (en) 2007-05-04 2008-11-13 Irm Llc Compounds and compositions as c-kit and pdgfr kinase inhibitors
ATE544761T1 (de) 2007-05-04 2012-02-15 Irm Llc Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
KR20120107538A (ko) 2007-08-22 2012-10-02 아이알엠 엘엘씨 키나제 억제제로서의 5-(4-(할로알콕시)페닐)피리미딘-2-아민 화합물 및 조성물

Also Published As

Publication number Publication date
MX2010002005A (es) 2010-03-11
AU2008289135B2 (en) 2012-02-23
AU2008289135A1 (en) 2009-02-26
WO2009026204A1 (en) 2009-02-26
EP2190836A1 (de) 2010-06-02
CN101784539A (zh) 2010-07-21
US8288540B2 (en) 2012-10-16
EP2190836B1 (de) 2011-08-17
US20110053952A1 (en) 2011-03-03
JP5303557B2 (ja) 2013-10-02
KR101171488B1 (ko) 2012-08-07
CA2697077A1 (en) 2009-02-26
KR20100050554A (ko) 2010-05-13
CA2697077C (en) 2012-10-16
BRPI0815572A2 (pt) 2015-02-18
EA201000325A1 (ru) 2010-10-29
JP2010536865A (ja) 2010-12-02
EA017392B1 (ru) 2012-12-28
ES2368876T3 (es) 2011-11-23

Similar Documents

Publication Publication Date Title
ATE520682T1 (de) 2-heteroarylaminopyrimidinderivate als kinaseinhibitoren
MX2009004141A (es) Composiciones y metodos para modular receptores de c-kit y pdgfr.
TN2010000087A1 (en) 5-(4- haloalkoxy) phenyl pyrimidine -2- aminecompounds and compositons as kinase inhibitors
WO2005034869A3 (en) Compounds and compositions as protein kinase inhibitors
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
ATE499374T1 (de) Verbindungen und zusammensetzungen als proteinkinase-hemmer
MY144044A (en) Compounds and compositions as protein kinase inhibitors
MX2008001605A (es) Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
EA201000003A1 (ru) Ингибиторы протеинкиназ и способы их применения
MX2009003649A (es) Inhibidores de cinasa de proteina y metodos para utilizarlos.
MX2008001969A (es) Compuestos y composiciones como inhibidores de proteina cinasa.
MX2009003456A (es) Compuestos y composiciones como inhibidores de proteina cinasa.
EA200901654A1 (ru) Ингибиторы и способы с их использованием
ATE469151T1 (de) Pyrrolopyridinderivate als proteinkinaseinhibitoren
WO2006124731A3 (en) Compounds and compositions as protein kinase inhibitors
TNSN07176A1 (en) Compounds and compositions as protein kinase inhibitors
EA201071089A1 (ru) Производные хиназолина как модуляторы raf-киназы и способы их применения
WO2010009342A3 (en) Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
MY182533A (en) Benzoxazole kinase inhibitors and method of use
TW200726766A (en) Compounds and compositions as protein kinase inhibitors
WO2008112695A3 (en) Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
WO2005039486A3 (en) Compounds and compositions as protein kinase inhibitors
WO2005030151A3 (en) Compounds and compositions as protein kinase inhibitors
DOP2009000083A (es) Composiciones y metodos para modular recpetores de pdgfr y c-kit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties